Back to Search Start Over

Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial

Authors :
David Cognetti
Tingting Zhan
Diana Whitaker Menezes
Michelle L. Reyzer
Patrick Tassone
Marina Domingo Vidal
Madalina Tuluc
Kurren S. Gill
Zhao Lin
Paolo Cotzia
Benjamin E. Leiby
Elizabeth Duddy
Adam Luginbuhl
Ubaldo E. Martinez-Outschoorn
Joseph Curry
John Sprandio
Jennifer Johnson
Ruth Birbe
Mehri Mollaee
Source :
The Laryngoscope. 127(8)
Publication Year :
2016

Abstract

Objective The tumor microenvironment frequently displays abnormal cellular metabolism, which contributes to aggressive behavior. Metformin inhibits mitochondrial oxidative phosphorylation, altering metabolism. Though the mechanism is unclear, epidemiologic studies show an association between metformin use and improved outcomes in head and neck squamous cell carcinoma (HNSCC). We sought to determine if metformin alters metabolism and apoptosis in HNSCC tumors. Study Design Window of opportunity trial of metformin between diagnostic biopsy and resection. Participants were patients with newly diagnosed HNSCC. Fifty patients were enrolled, and 39 completed a full-treatment course. Metformin was titrated to standard diabetic dose (2,000 mg/day) for a course of 9 or more days prior to surgery. Methods Immunohistochemistry (IHC) for the metabolic markers caveolin-1 (CAV1), B-galactosidase (GALB), and monocarboxylate transporter 4 (MCT4), as well as the Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) apoptosis assay and Ki-67 IHC, were performed in pre- and postmetformin specimens. Exploratory mass spectroscopy imaging (MSI) to assess lactate levels also was performed in three subjects. Results Metformin was well tolerated. The average treatment course was 13.6 days. Posttreatment specimens showed a significant increase in stromal CAV1 (P < 0.001) and GALB (P < 0.005), as well as tumor cell apoptosis by TUNEL assay (P < 0.001). There was no significant change in stromal MCT4 expression or proliferation measured by Ki67. Lactate levels in carcinoma cells were increased 2.4-fold postmetformin (P < 0.05), as measured by MSI. Conclusion Metformin increases markers of reduced catabolism and increases senescence in stromal cells as well as carcinoma cell apoptosis. This study demonstrates that metformin modulates metabolism in the HNSCC microenvironment. Level of Evidence 4. Laryngoscope, 127:1808–1815, 2017

Details

ISSN :
15314995
Volume :
127
Issue :
8
Database :
OpenAIRE
Journal :
The Laryngoscope
Accession number :
edsair.doi.dedup.....ee95da23d80b0ae911eecff856584d1a